Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00825227 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents
A Phase 2 study, sponsored by Cephalon.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00825227 is a Phase 2 study that was terminated before completion, run by Cephalon. The registered enrollment target is 10 participants.
The verdict
NCT00825227, a Phase 2 study, was terminated before completion, sponsored by Cephalon.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Evaluate the Safety and Efficacy of Armodafinil Treatment for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents
Interventions
- DRUG Armodafinil 150 mg/day
- DRUG Placebo,
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00825227
The ClinicalTrials.gov registry entry for NCT00825227 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Armodafinil 150 mg/day is the first listed.
NCT00825227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00825227 about?
NCT00825227 is a clinical study titled "Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents". Evaluate the Safety and Efficacy of Armodafinil Treatment for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents
What is the current status of trial NCT00825227?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2008-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00825227?
The interventions under investigation include: Armodafinil 150 mg/day (DRUG), Placebo, (DRUG).
Who is sponsoring clinical trial NCT00825227?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.